Loading market dashboard
Medicus Pharma Ltd. Common Stock
MDCXHealthcareNASDAQCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the filing of a registration study with the US Food and Drug Administration (FDA) for its SkinJect program targeting patients with Gorlin syndrome, marking a potentially important step toward commercialization of the technology. Speaking with Proactive, chief executive Raza Bokhari said the company has continued to advance SkinJect, a non-invasive treatment platform designed for non-melanoma skin diseases, particularly basal cell carcinoma.
Medicus Pharma (NASDAQ:MDCX) earlier this week announced the filing of a registration study with the US Food and Drug Administration (FDA) for its SkinJect...
Solidion Technology (NASDAQ:STI) shares added as much as 500% on Thursday after the battery technology developer announced a patented advancement aimed at...
The filing sets a $1.785 trillion implied market capitalisation at the $135 offer price, but prediction market traders are already betting heavily that...
7.16am: FTSE heading lower at open, despite Gulf developments The FTSE 100 could well spend another day in red on Thursday, after sharp falls on Wall Street...
Medicus Pharma (NASDAQ:MDCX) announced that it has submitted Protocol SKNJCT-005 to the US Food and Drug Administration (FDA) under its existing Investigational New Drug (IND) application for SkinJect, advancing the therapy into registrational development for patients with Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome (NBCCS). The company said the protocol outlines a Phase 2b, open-label study intended to generate efficacy and safety data that could support a future New Drug Application (NDA) for SkinJect in the rare inherited disorder.
PHILADELPHIA, June 03, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced the submission of Protocol SKNJCT-005 to the U.S. Food and Drug Administration (FDA) under the Company's existing Investigational New Drug (IND) application, for SkinJect® into registrational development for patients with Gorlin Syndrome, also called Nevoid Basal Cell Carcinoma Syndrome (NBCCS), a rare inherited genetic disorder associated with lifelong development of multiple basal cell carcinomas and recurrent skin cancers, often resulting in repeated surgical procedures.
Medicus Pharma (NASDAQ:MDCX) announced that it has submitted Protocol SKNJCT-005 to the US Food and Drug Administration (FDA) under its existing...
UBS's Chief Investment Office maintains an "attractive" rating on equities despite persistent inflation pressures, arguing that solid corporate earnings...
4:20pm: New highs Wall Street closed higher on Thursday, with the S&P 500 and Nasdaq Composite climbing to fresh record highs as investors weighed a...
Medicus Pharma (NASDAQ:MDCX) announced on Thursday that it has entered into a definitive financing agreement with an institutional investor for an up to $22 million structured, non-dilutive financing facility aimed at supporting its clinical development programs and extending its cash runway. The biotech and life sciences company said the financing is expected to increase its pro forma cash position to about $30 million and provide projected operating liquidity for more than 24 months.
Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years Financing Provides Immediate Growth Capital to Support Clinical Development Initiatives and Extends Projected Operating Cash Runway for Over Two (2) Years
Synopsys Inc (NASDAQ:SNPS, XETRA:SYP) reported fiscal second quarter results above Wall Street expectations, with adjusted earnings and revenue both...
Medicus Pharma (NASDAQ:MDCX) reported first quarter 2026 financial results on Thursday, highlighting progress across its SkinJect and Teverelix clinical programs while continuing efforts to strengthen its financing position. The biotech company said it recently reported positive expanded Phase 2 data for its SkinJect Doxorubicin Microneedle Array treatment for nodular basal cell carcinoma, including what it described as registrational-grade clearance rates in the 200-microgram treatment cohort.
Medicus Pharma (NASDAQ:MDCX) reported first quarter 2026 financial results on Thursday, highlighting progress across its SkinJect and Teverelix clinical...
Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives Company Advances SkinJect® and Teverelix® Clinical Programs While Strengthening Financing Flexibility and Expanding Strategic Development Initiatives
JD Sports Fashion PLC (LSE:JD., OTC:JDSPY) shares jogged 3% higher to 70.02p after the retailer hiked its dividend 20% and launched a £200 million buyback,...
Medicus Pharma (NASDAQ:MDCX) has reported additional results from a pre-specified expanded dataset analysis of its Phase 2 SKNJCT-003 trial, showing a positive dose-response relationship for its Doxorubicin Microneedle Array (D-MNA) in treating nodular basal cell carcinoma (BCC). The analysis builds on previously disclosed topline results and incorporates biological, histologic, and safety data from a refined group of 69 patients whose diagnoses met the study's intended inclusion criteria.
Shares of Uber Technologies Inc (NYSE:UBER, XETRA:UT8) jumped 8.4% on Wednesday after the ride-hailing and delivery giant reported first-quarter results...
PHILADELPHIA, May 06, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today announced results from a pre-specified expanded dataset analysis demonstrating positive dose response from its Phase 2 SKNJCT-003 study evaluating safety and efficacy of Doxorubicin Microneedle Array (D-MNA) to treat nodular basal cell carcinoma (BCC) of the skin, the most common type of skin cancer.
Medicus Pharma (NASDAQ:MDCX) has reported additional results from a pre-specified expanded dataset analysis of its Phase 2 SKNJCT-003 trial, showing a...
Medicus Pharma (NASDAQ:MDCX) said on Monday its chief executive and senior leadership team met with US lawmakers on Capitol Hill to seek support for regulatory and policy measures aimed at advancing its SkinJect therapy for patients with Gorlin syndrome, a rare inherited condition linked to recurrent skin cancers. The biotech company said the discussions focused on securing orphan drug designation for SkinJect for Gorlin syndrome, registrational investigational new drug approval for affected patients, and support for the rare disease pediatric FDA voucher program.
Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease Builds Support for Accelerated Access to SkinJect® for Gorlin Syndrome patients with a Rare Autosomal Dominant Disease
Medicus Pharma (NASDAQ:MDCX) said on Monday its chief executive and senior leadership team met with US lawmakers on Capitol Hill to seek support for...
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in advancing its Skinject program, highlighting a newly submitted orphan drug designation application with the US Food and Drug Administration targeting Gorlin syndrome, a rare genetic condition with no approved treatments. In an interview with Proactive, CEO Dr Raza Bokhari said the company is positioning 2026 as a “catalyst rich year,” driven by developments across its pipeline, led by Skinject.
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in advancing its Skinject program, highlighting a newly submitted orphan drug designation...
Medicus Pharma (NASDAQ:MDCX) said on Friday it has submitted an application to the US Food and Drug Administration seeking orphan drug designation for its SkinJect therapy to treat basal cell carcinoma in patients with Gorlin Syndrome, a rare genetic condition marked by recurring skin cancers. The company said the filing expands its SkinJect program into an area of high unmet medical need, where treatment options are limited and often rely on repeated surgical procedures that can lead to cumulative physical and psychological burden.
Microsoft Corp (NASDAQ:MSFT) is set to report fiscal third-quarter 2026 earnings on April 29, with investors closely watching whether accelerating...
Amneal Pharmaceuticals Inc (NASDAQ:AMRX) shares rose 5.7% on Friday after UBS initiated coverage with a Buy rating and a $19 price target, citing what it...
Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinoma Targets rare, high-burden genetic condition with no approved therapies; advances non-surgical treatment strategy for recurrent basal cell carcinoma
Medicus Pharma (NASDAQ:MDCX) said on Friday it has submitted an application to the US Food and Drug Administration seeking orphan drug designation for its...
Medicus Pharma (NASDAQ:MDCX) announced plans to present new early-stage clinical data on its investigational drug candidate, Teverelix, at the American Association of Clinical Endocrinology (AACE) Annual Meeting 2026 in Las Vegas later this month. The company said the presentation will include results from two Phase 1 studies evaluating Teverelix, a long-acting gonadotropin-releasing hormone (GnRH) antagonist being developed for hormone-related conditions.
Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women's Health Updated Safety, Efficacy, and Clinical Data Supports Teverelix as Potentially the First Long-Acting Injectable GnRH Antagonist Across Multiple Indications in Women's Health
The company positions Teverelix, a next-generation GnRH antagonist, as a first-in-market product targeting cardiovascular high-risk advanced prostate cancer patients and those with acute urinary retention relapse (AURr) episodes due to enlarged prostate. The company said it collectively represents an approximately $6 billion market opportunity.
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in the development of its investigational therapy Teverelix, confirming that it has submitted an optimized Phase 2 study design to the US Food and Drug Administration targeting acute urinary retention (AUR) relapse prevention. Speaking to Proactive, chief medical officer Dr Faisal Mehmud said the company is refining its clinical approach to improve both efficiency and speed of decision-making.
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in the development of its investigational therapy Teverelix, confirming that it has...
4.15pm: Deadline eyed US stocks finished the day on the front foot on hopes that a ceasefire deal will be reached between the US and Iran before Trump’s...
Boot Barn (NYSE:BOOT) has been upgraded to a ‘Buy’ rating from ‘Hold’ by Jefferies analysts, who cited a significant reset in valuation alongside resilient...
Bank of America shifted its rating on Carvana Co. (NYSE:CVNA) to Neutral on Monday, signaling a more cautious near-term outlook for the online used-car...
Medicus Pharma (NASDAQ:MDCX) announced on Monday that it has submitted an optimized Phase 2 clinical study protocol to the US Food and Drug Administration (FDA) for Teverelix, an investigational GnRH antagonist. The study is designed to evaluate the drug's effectiveness in preventing recurrent acute urinary retention (AURr) in men with benign prostatic hyperplasia (BPH) as part of an existing open Investigational New Drug application.
Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market Mechanism-Driven Study Design Focused on Capital Efficiency and Accelerated Development for Near-Term Value Creation, Addressing a $2 Billion Potential Target Market
The revised trial design focuses on evaluating Teverelix, a GnRH antagonist, for preventing recurrent acute urinary retention in men with benign prostatic hyperplasia.
Medicus Pharma (NASDAQ:MDCX) announced on Monday that it has submitted an optimized Phase 2 clinical study protocol to the US Food and Drug Administration...
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined further progress in its Skinject program following the release of Phase 2 topline data, alongside independent validation from a leading dermatology expert. The company's CEO Raza Bokhari said Medicus Pharma is advancing a novel, noninvasive treatment using patent-protected microneedle arrays designed to treat non-melanoma skin diseases, particularly basal cell carcinoma.
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined further progress in its Skinject program following the release of Phase 2 topline data, alongside...
Medicus Pharma (NASDAQ:MDCX) said on Wednesday its Phase 2 study of SkinJect (SKNJCT-003), a doxorubicin-containing microneedle array for nodular basal cell carcinoma (BCC), showed clinically meaningful activity, supporting plans to advance the therapy toward registrational development. “We believe the positive topline results from 200 ug cohort at day 57, support the therapeutic value of SkinJect and establishes the best path forward towards registrational study,” said Dr. Raza Bokhari, executive chairman and CEO of Medicus.
Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancer Provides guidance on interpretation of Topline dataset and confirms focus on drug-driven efficacy in non-melanoma skin cancer
Medicus Pharma (NASDAQ:MDCX) announced that an independent assessment of its Phase 2 SkinJect study supports the clinical relevance of the data and continued development of the experimental therapy for non-melanoma skin cancer. The evaluation was provided by Dr Babar Rao, principal investigator of the SKNJCT-003 trial, who described the dataset as “clinically meaningful” and supportive of further trials and regulatory engagement.
Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer Dr. Babar Rao highlights clinically meaningful outcomes with majority of lesions potentially avoiding immediate surgery in non-melanoma Skin Cancer
Medicus Pharma Ltd (NASDAQ: MDCX - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 13th, there was short interest totaling 3,559,666 shares, a growth of 290.7% from the February 26th total of 911,128 shares. Approximately 15.7% of the shares of the stock are
4.20pm: Another day of losses With no end in sight for the Middle East conflict, stocks remained under pressure while oil prices moved higher on Thursday....
Medicus Pharma (NASDAQ:MDCX) said on Thursday it is entering a “catalyst-rich” 2026 after reporting annual results and highlighting progress across its SkinJect and Teverelix programs, alongside expansion into precision medicine and AI-enabled clinical development. The clinical-stage biotech said 2025 marked a pivotal year, driven by completion of a Phase 2 study for SkinJect and efforts to broaden its pipeline into rare diseases and women's health.
Wave Life Sciences (NASDAQ:WVE) saw its shares fall more than 52% following the release of six-month Phase 1 data for WVE-007, its investigational INHBE...
200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer 200µg Cohort at Day 57 Dataset suggests majority of treated Lesions may Avoid Surgery as Company targets larger unmet medical need in Non-melanoma Skin Cancer
Advances Clinical Pipeline Across Dermatology, Urology, Oncology and strengthens Capital Base to support Phase 2 Programs PHILADELPHIA, PA / ACCESS Newswire / March 25, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, today reported audited financial results for the year ended December 31, 2025, and provided a corporate update highlighting significant progress across its SkinJect® and Teverelix development programs, as well as expansion into precision medicine and AI-enabled clinical development.
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention. PHILADELPHIA, PA / ACCESS Newswire / March 18, 2026 / Medicus Pharma Ltd.
Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.
Medicus Pharma (NASDAQ:MDCX) earlier this week highlighted encouraging data from its Phase 2 clinical trial evaluating SkinJect, a non-invasive treatment designed to address basal cell carcinoma, the most common form of skin cancer. Speaking to Proactive, chief executive Raza Bokhari said the latest dataset suggests the company's microneedle-based therapy could significantly reduce the need for surgical intervention in many patients.
Medicus Pharma (NASDAQ:MDCX) earlier this week highlighted encouraging data from its Phase 2 clinical trial evaluating SkinJect, a non-invasive treatment...
Dr. Raza Bokhari, Executive Chairman & CEO will participate in panel discussions and highlight Company's AI-enabled Drug Development Strategy PHILADELPHIA, PA / ACCESS Newswire / March 10, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce its participation in the Longwood Miami CEO forum being held March 11-13, 2026, at the Ritz-Carlton Key Biscayne.
